Shanghai Fosun Pharmaceutical Fosun Pharma and US private equity firm TPG have made an offer to take Nasdaq-listed healthcare company Chindex private in a $369 million deal.
The move offers TPG the chance to gain exposure to China's growing healthcare sector, an area that the government has been loosening restrictions on.
It also will enable the Chinese group’s management to partner two deep-pocketed players in its expansion drive.
Fosun Pharma already holds a 17.4% stake in Chindex and, after the deal, this will rise to 48.6%. TPG's stake will be 48.1% and the management's stake, including that of chief executive Roberta Lipson, will...